Cantor Fitzgerald provided analyst coverage and targets for Esperion Therapeutics.
1 report, 1 independent
Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald provided analyst coverage and targets for Esperion Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
Esperion Therapeutics
American pharmaceutical company
Nothing else this week.
Related events
- Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
- Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma on August 20, 2025.
- Cantor Fitzgerald hosted a healthcare conference on September 8, 2026.
- Analyst provides a high price target for Viking Therapeutics stock.
- Cantor Fitzgerald provided research reports on Cabaletta Bio, a company whose stock trades on Nasdaq.